Physician profile
Michael Lichardi
NPI 1134198724
$702.18
in general payments reported to CMS, 2019-2025
13 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.65 · 2022: $34.35 · 2023: $20.23 · 2024: $211 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.40 | 2024-2025 | |
| Gilead Sciences, INC. | $107.10 | 2024 | Veklury |
| Shionogi INC | $104.67 | 2022-2025 | Fetroja |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.96 | 2024-2025 | Xifaxan |
| Becton, Dickinson and Company | $45.21 | 2021 | |
| Angiodynamics, INC. | $34.65 | 2021-2022 | |
| Terumo Medical Corporation | $34.35 | 2024 | Azur Cx Detachable |
| Medtronic, INC. | $20.00 | 2025 | Osteocool Rf Ablation System |
| Lundbeck LLC | $18.67 | 2025 | Vyepti |
| Tanabe Pharma America, INC. | $18.56 | 2025 | Radicava |
| Argon Medical Devices, INC. | $15.38 | 2021 | |
| Boston Scientific Corporation | $14.83 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.40 | 2025 | Xeomin, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lichardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.